OWC Pharmaceutical Research Corp (OWCP)

[Triple9]

Someone else posted this line of attack the other day, so seems he's found a crap website to post the same crap. Account is 2 days old. LOL. Don't feed the troll with clicks. I've posted the gist of it here:

Many factors point towards a red flag:

1) This company is based overseas, and conducts research overseas, meaning there are very few ways to monitor their progress when it comes to their claims.

2) This is still a pennystock, while some might be tempted to take risks, the slightest mistake by the company will cause investors to lose all their money, rapidly.

3) If the pharmaceutical research fails, the owners could dump their shares knowing they cannot profit further from this venture, causing investors to lose their money.

4) The only product they got going for them is a skin cream, and this has very little impact of the market as it is.

1. Ignorant and frankly Racist. "It's not US, therefore it's bad." Give me a break. Our safety study is taking place at the largest, most respected hospital in the Middle East. Period.

2. Well it's a good thing OWCP has been so careful and strategic in all of it's moves! If this guy had done any DD whatsoever he'd know what we know. Some people are impatient with PPS. I sometimes think OWCP is overly cautious. But at the end of the day, I like a company that is overly cautious versus one that is not cautious enough.

3. OWCP has delivery system technology, consulting expertise, and a vast pipeline with patents protection initiated years ago. Two delivery systems are done and ready to market. 2 on the back burner. Cannabis is Proven. MMJ is Proven.

4. Wrong again. No DD whatsoever. Consulting agreements. Licensing agreements. Psoriasis cream. Other skin creams. Multiple Myeloma in the pipeline. PTSD in the pipeline. Migraines in the pipeline.

OWCP is being very smart and strategic. The revenue from the Q2+ skin creams will be immediately applied to the next phase of clinical trials for Multiple Myeloma, PTSD, Migraines and, now, with Dr. Rosenblat's expertise, perhaps skin cancer.

We have so much to look forward to in 2017, 2018 and beyond!